Skip to main content
Premium Trial:

Request an Annual Quote

Texas to Spend $50M on New Institute for Genomic Medicine

NEW YORK, July 18 (GenomeWeb News) - The state of Texas has committed $50 million from the Texas Enterprise Fund to establish the Texas Institute for Genomic Medicine, which will offer a mouse stem cell library to researchers, Lexicon Genetics said last week.


Lexicon will receive $35 million of the award to create a library of 350,000 knockout mouse embryonic stem cell lines. The remaining $15 million will go to the Texas A&M University System for creating facilities and infrastructure to house the library.


Founding members of the non-profit institute are TexasA&MUniversity, the TexasA&MUniversitySystemHealthScienceCenter, and Lexicon Genetics, but the institute encourages participation by all Texasacademic, medical, and commercial entities. The institute will focus on diabetes and obesity research as well as infectious diseases and cancer and will offer its mouse stem cell library to researchers worldwide. It will be located at the TexasA&MSystemHealthScienceCenter's Instituteof Biosciencesand Technology in Houstonand at TexasA&MUniversityin Houston.

The Scan

Study Links Genetic Risk for ADHD With Alzheimer's Disease

A higher polygenic risk score for attention-deficit/hyperactivity disorder is also linked to cognitive decline and Alzheimer's disease, a new study in Molecular Psychiatry finds.

Study Offers Insights Into Role of Structural Variants in Cancer

A new study in Nature using cell lines shows that structural variants can enable oncogene activation.

Computer Model Uses Genetics, Health Data to Predict Mental Disorders

A new model in JAMA Psychiatry finds combining genetic and health record data can predict a mental disorder diagnosis before one is made clinically.

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.